Precision Medicine for Older AML Patients
Open Access
Abstract
The development of molecular profiling approaches for AML patients such as whole genome sequencing, whole exome sequencing and transcriptomic sequencing have greatly contributed to better understanding of leukemia development, progression and treatment responsiveness/resistance. These studies have generated a new knowledge about driver events operating in AML that can be translated into clinics, thus favoring the mutations; using this approach, more than 50% of older AML patients display molecular alterations, such as IDH1, IDH2, FLT3 (FLT3-TKD and FLT3-ITD), NPM1 and KMT2A rearrangements that can be targeted by specific drugs. Preclinical and clinical studies have supported the use of drugs targeting these molecular alterations as first-line therapy in association with induction chemotherapy in chemotherapy-fit patients or with a hypomethylating agent in association with a Bcl-2 inhibitor (Venetoclax) in chemotherapy-unfit patients. These studies have shown promising results that need to be confirmed through randomized clinical studies specifically involving the enrollment of older AML patients.Keywords
This publication has 130 references indexed in Scilit:
- Applications of machine learning for immunophenotypic measurable residual disease assessment in acute myeloid leukemiaHemaSphere, 2025
- Age‐stratified machine learning identifies divergent prognostic significance of molecular alterations in AMLHemaSphere, 2025
- Drug Sensitivity patterns across FAB subtypes and molecular mutations in AML: A comprehensive analysis for precision medicineClinical and Translational Discovery, 2025
- A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukemiaCancer, 2025
- Models for the marrow: A comprehensive review of AI‐based cell classification methods and malignancy detection in bone marrow aspirate smearsHemaSphere, 2024
- Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemiaBlood Neoplasia, 2024
- Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groupsAmerican Journal of Hematology, 2024
- Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master TrialCancer, 2023
- Role of ASXL1 in hematopoiesis and myeloid diseasesExperimental Hematology, 2022
- Integrative analysis of drug response and clinical outcome in acute myeloid leukemiaCancer Cell, 2022